Repurposed drug battles 'brain-eating' amoeba

Area of Science:

• Infectious Diseases
• Parasitology
• Pharmacology

Background:

• Balamuthia mandrillaris is a rare, free-living amoeba causing granulomatous amebic encephalitis (GAE) and other infections.
• Current treatments for Balamuthia infections are limited and often ineffective, with high mortality rates.
• Urinary tract infection (UTI) drugs are widely available and well-characterized.

Observation:

• A specific drug commonly used for urinary tract infections demonstrated in vitro activity against Balamuthia mandrillaris.
• The drug's mechanism of action may be relevant for targeting amoebic pathogens.

Findings:

• The UTI drug effectively inhibited the growth and survival of Balamuthia mandrillaris in laboratory settings.
• Further studies are warranted to explore its efficacy and safety in vivo.

Implications:

• This finding suggests a potential repurposed drug for treating Balamuthia infections, offering a new therapeutic avenue.
• Repurposing existing drugs could expedite treatment development and reduce costs for rare diseases.
• Highlights the potential for discovering novel treatments by screening existing drug libraries.